Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Opening Remarks:
• Current Hot Issues for DDI (Ken Thummel, University of Washington, Seattle)
• Comparison Between the New US FDA and Japan PMDA In Vitro DDI Guidance: Are we
Close to Harmonization? (Brian Oglivie, Xenotech)
• What Can Be Learned from Recent NDAs? Key Findings on Drug Interactions for Drugs
Approved by the FDA in 2017 (Jingjing Yu, University of Washington)
• Strategies for Developing and Validating PBPK Models for Extrapolation to Unstudied
Population (Nina Isoherranen, University of Washington)
Session 5: Unresolved Issues and Novel Technologies for DDI Evaluation (Chair: Albert P.
Li)
• Transporter Drug-Drug Interactions: An Evaluation of Approaches and Methodologies (Rob
Elsby, Evotec)
• Evaluation of Endogenous Biomarkers for Transporter Inhibition: Current State and Future
Considerations (Xiaoyan Chu, Merck)